# üìä Ersilia Statistics Report

_Last updated: 2025-01-04 14:23:56 GMT_

## üß¨ Models' Impact

- **Total Models:** 181
- **Percentage Ready to Use:** 85.08%

<details>
<summary>Model Categorization</summary>

| Category | Count |
| --- | --- |
| ADME | 28 |
| Descriptor | 26 |
| Chemical graph model | 23 |
| Toxicity | 20 |
| Similarity | 16 |
| Embedding | 16 |
| Compound generation | 14 |
| Permeability | 13 |
| Metabolism | 13 |
| Fingerprint | 13 |
| MoleculeNet | 12 |
| Chemical language model | 11 |
| Antimicrobial activity | 11 |
| ChEMBL | 10 |
| Untagged | 9 |
| IC50 | 8 |
| Solubility | 7 |
| Chemical synthesis | 7 |
| Chemical notation | 7 |
| Human | 6 |
| M.tuberculosis | 6 |
| Cardiotoxicity | 6 |
| Dummy | 6 |
| P.falciparum | 6 |
| Malaria | 6 |
| Natural product | 5 |
| CYP450 | 5 |
| Drug-likeness | 5 |
| LogP | 5 |
| Antiviral activity | 5 |
| Synthetic accessibility | 5 |
| hERG | 5 |
| Half-life | 4 |
| Lipophilicity | 4 |
| Tuberculosis | 4 |
| Bioactivity profile | 4 |
| COVID19 | 4 |
| Microsomal stability | 3 |
| Cytotoxicity | 3 |
| Quantum properties | 3 |
| Sars-CoV-2 | 3 |
| Side effects | 2 |
| Papp | 2 |
| Target identification | 2 |
| LogS | 2 |
| pKa | 2 |
| BACE | 2 |
| ESKAPE | 2 |
| Alzheimer | 2 |
| E.coli | 2 |
| Tox21 | 2 |
| HIV | 2 |
| Fraction bound | 2 |
| Cancer | 2 |
| DrugBank | 2 |
| GPCR | 1 |
| N.gonorrhoeae | 1 |
| A.baumannii | 1 |
| Rat | 1 |
| HDAC1 | 1 |
| HBV | 1 |
| MIC90 | 1 |
| Price | 1 |
| ToxCast | 1 |
| Therapeutic indication | 1 |
| Schistosomiasis | 1 |
| Neglected tropical disease | 1 |
| Mycetoma | 1 |
| Antifungal activity | 1 |
| LogD | 1 |
| ZINC | 1 |
| Molecular weight | 1 |
| Biomedical text | 1 |


</details>

<details>
<summary>Most Recent Models</summary>

| Title | Contributor | Date | Status |
| --- | --- | --- | --- |
| Knowledge-guided pre-trained graph transformer | miquelduranfrigola | 2024-12-17 | In progress |
| Antimicrobial class specificity prediction | miquelduranfrigola | 2024-12-17 | In progress |
| MolE molecular embeddings | miquelduranfrigola | 2024-11-18 | In progress |
| Projections against Coconut | miquelduranfrigola | 2024-11-10 | In progress |
| Chemical space 2D projections against DrugBank | miquelduranfrigola | 2024-11-09 | In progress |


</details>

üëâ [Explore more models on our dashboard](https://ersilia.io/model-hub)


## üåç Community & Blog

- **Countries Represented:** 17
- **Total Contributors:** 91

<details>
<summary>Role Distribution</summary>

| Role | Count |
| --- | --- |
| Volunteer | 47 |
| Intern | 27 |
| Trustee | 5 |
| OS Maintainer | 4 |
| Mentor | 4 |
| MSc Student | 4 |
| Advisor | 2 |
| Employee | 2 |
| BSc Student | 2 |
| Visiting Researcher | 1 |


</details>

<details>
<summary>Duration of Involvement</summary>

| Duration | Count |
| --- | --- |
| < 3 Months | 63 |
| 3-6 Months | 14 |
| > 1 Year | 11 |
| 6-12 Months | 2 |


</details>

<details>
<summary>Contributors by Country</summary>

| Country | Contributors |
| --- | --- |
| United States | 48 |
| Nigeria | 9 |
| Spain | 9 |
| India | 7 |
| Australia | 3 |
| Colombia | 2 |
| Pakistan | 2 |
| Poland | 2 |
| Kenya | 1 |
| Uganda | 1 |
| South Africa | 1 |
| United Kingdom | 1 |
| Cameroon | 1 |
| Italy | 1 |
| Singapore | 1 |
| Serbia | 1 |
| Namibia | 1 |


</details>


## üìù Blogposts

- **Total Blogposts:** 50

<details>
<summary>Blogpost Topics Distribution</summary>

| Topic | Count | Percentage |
| --- | --- | --- |
| AI/ML in Drug Discovery | 17 | 34.69% |
| Ersilia Open Source Initiative | 12 | 24.49% |
| Funding & Partnerships | 6 | 12.24% |
| Personal Reflections | 6 | 12.24% |
| Open Science | 3 | 6.12% |
| Software Development & Tools | 3 | 6.12% |
| Global Health | 2 | 4.08% |


</details>

<details>
<summary>Blogposts Over Time</summary>

| Year | Quarter | Post Count |
| --- | --- | --- |
| 2021 | Q2 | 6 |
| 2021 | Q3 | 4 |
| 2021 | Q4 | 2 |
| 2022 | Q1 | 3 |
| 2022 | Q2 | 2 |
| 2022 | Q3 | 4 |
| 2022 | Q4 | 2 |
| 2023 | Q1 | 2 |
| 2023 | Q2 | 3 |
| 2023 | Q3 | 4 |
| 2023 | Q4 | 4 |
| 2024 | Q1 | 3 |
| 2024 | Q2 | 3 |
| 2024 | Q3 | 2 |
| 2024 | Q4 | 3 |


</details>


## üè¢ Organizations in Ersilia's Network

- **Total Organizations:** 209

<details>
<summary>Organization Types</summary>

| Type | Count |
| --- | --- |
| Academia | 61 |
| Foundation | 49 |
| Nonprofit | 33 |
| Corporate | 31 |
| Pharma | 14 |
| Government | 11 |
| Accelerator | 8 |


</details>

<details>
<summary>Organizations by Country</summary>

| Country | Total Organizations |
| --- | --- |
| United States | 102 |
| United Kingdom | 25 |
| Spain | 23 |
| South Africa | 9 |
| Switzerland | 8 |
| Cameroon | 5 |
| Belgium | 5 |
| Germany | 4 |
| Brazil | 3 |
| Ghana | 3 |
| Kenya | 2 |
| Zambia | 2 |
| Guinea | 2 |
| Mexico | 1 |
| Austria | 1 |
| Australia | 1 |
| United Arab Emirates | 1 |
| Netherlands | 1 |
| Gambia | 1 |
| France | 1 |
| Japan | 1 |
| Italy | 1 |
| Zimbabwe | 1 |
| Singapore | 1 |
| Tanzania | 1 |
| Unknown | 1 |


</details>


## üèÖ Author Highlights

- **Total Authors:** 217
- **Top Author:** Patrick Aloy (H-index: 54)

<details>
<summary>Top Authors</summary>

| Name | Ersilia Pubs | H-index | Total Pubs |
| --- | --- | --- | --- |
| Patrick Aloy | 2 | 54.0 | 16 |
| Kelly Chibale | 2 | 39.0 | 2 |
| Izukanji Sikazwe | 2 | 25.0 | 2 |


</details>

<details>
<summary>Patrick Aloy - See Publications ‚¨áÔ∏è</summary>

| Title | Year | URL |
| --- | --- | --- |
| Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque | 2022 | https://www.nature.com/articles/s41467-022-33026-0 |
| Connecting chemistry and biology through molecular descriptors | 2021 | https://www.sciencedirect.com/science/article/pii/S1367593121001204?via%3Dihub |


</details>
<details>
<summary>Kelly Chibale - See Publications ‚¨áÔ∏è</summary>

| Title | Year | URL |
| --- | --- | --- |
| First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa | 2023 | https://www.nature.com/articles/s41467-023-41512-2 |
| AI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa | 2024 | https://www.medrxiv.org/content/10.1101/2024.11.07.24316884v1 |


</details>
<details>
<summary>Izukanji Sikazwe - See Publications ‚¨áÔ∏è</summary>

| Title | Year | URL |
| --- | --- | --- |
| Cervical cancer screening outcomes in Zambia, 2010‚Äì19: a cohort study | 2021 | https://www.sciencedirect.com/science/article/pii/S2214109X21000620 |
| Evaluation of kidney function among people living with HIV initiating antiretroviral therapy in Zambia | 2022 | https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000124 |


</details>


## üåê External Data

<details>
<summary>Disease Statistics</summary>

| Disease | Estimated Total Cases | Estimated Total Deaths |
| --- | --- | --- |
| Hivaids | - | 27,580,837 |
| Covid | 777,074,039 | 7,079,129 |
| Malaria | - | 15,317,311 |
| Tb | 253,467,432 | 44,118,898 |
| Cancer | - | 178,651,923 |
| Measles | 47,347,773 | - |
| Polio | 541,429 | - |


</details>


---
The full data output that this report is based on can be found in `data/` and `external-data/`. An abbreviated version can be found in `reports/table_stats.json`.